Secondary Logo

Journal Logo

Walsh Christina; Wernz, James C.; Levine, Alexandra; Rarick, Mark; Willson, Esther; Melendez, Debbie; Bonnem, Eric; Thompson, James; Shelton, Brent
Journal of Acquired Immune Deficiency Syndromes: March 1993
CLINICAL SCIENCE: PDF Only
Free

The use of full-dose intensive regimens of chemotherapy in patients with HIV-associated lymphoma has often resulted in severe toxicity, treatment delay, and reduced subsequent dosing. We conducted a Phase I trial to evaluate the toxicity of the combination of m-BACOD (methotrexate, Bleomycin, doxorubicin, cyclophosphamide, vincristine. dexamethasone) with granulocyte-macrophage colony stimulating factor (GMCSF) in these patients. A total of 17 patients were entered and treated at three dose levels of m-BACOD in combination with a fixed dose of GMCSF. Eight patients received standard dose m-BACOD plus GMCSF without experiencing dose-limiting hematologic toxicity, although significant nonhematologic toxicity was seen. We conclude that it is feasible to treat patients with HIV-associated lymphoma using standard dose m-BACOD plus GMCSF, but further study is needed to determine whether full-dose regimens improve survival when compared with reduced dose regimens in these individuals.

© Lippincott-Raven Publishers.